AU2021401282A1 - Kinase inhibitors and uses thereof - Google Patents

Kinase inhibitors and uses thereof Download PDF

Info

Publication number
AU2021401282A1
AU2021401282A1 AU2021401282A AU2021401282A AU2021401282A1 AU 2021401282 A1 AU2021401282 A1 AU 2021401282A1 AU 2021401282 A AU2021401282 A AU 2021401282A AU 2021401282 A AU2021401282 A AU 2021401282A AU 2021401282 A1 AU2021401282 A1 AU 2021401282A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021401282A
Other languages
English (en)
Inventor
Chen Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaica Medicines Inc
Original Assignee
Mosaica Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaica Medicines Inc filed Critical Mosaica Medicines Inc
Publication of AU2021401282A1 publication Critical patent/AU2021401282A1/en
Assigned to MOSAICA MEDICINES, INC. reassignment MOSAICA MEDICINES, INC. Request for Assignment Assignors: ABM THERAPEUTICS CORPORATION
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021401282A 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof Pending AU2021401282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126364P 2020-12-16 2020-12-16
US63/126,364 2020-12-16
PCT/US2021/063724 WO2022133040A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2021401282A1 true AU2021401282A1 (en) 2023-07-13

Family

ID=79425572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021401282A Pending AU2021401282A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Country Status (9)

Country Link
US (1) US20240083844A1 (https=)
EP (1) EP4263501A1 (https=)
JP (1) JP2023554391A (https=)
KR (1) KR20230144529A (https=)
CN (1) CN117083265A (https=)
AU (1) AU2021401282A1 (https=)
CA (1) CA3179325A1 (https=)
MX (1) MX2023006434A (https=)
WO (1) WO2022133040A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116356017A (zh) * 2022-12-12 2023-06-30 南京腾辰生物科技有限公司 一种甲状腺肿瘤良恶性早期诊断标志物及其应用
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200703912B (en) * 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
GB0812913D0 (en) * 2008-07-15 2008-08-20 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN102666512B (zh) * 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
WO2012055953A1 (en) * 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
AU2013266438B2 (en) * 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Also Published As

Publication number Publication date
EP4263501A1 (en) 2023-10-25
JP2023554391A (ja) 2023-12-27
MX2023006434A (es) 2023-06-13
WO2022133040A1 (en) 2022-06-23
CA3179325A1 (en) 2022-06-23
CN117083265A (zh) 2023-11-17
US20240083844A1 (en) 2024-03-14
KR20230144529A (ko) 2023-10-16

Similar Documents

Publication Publication Date Title
JP7850663B2 (ja) スピロ環含有キナゾリン化合物
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
EP3519398B1 (en) Pyridine compound
CN107531682B (zh) B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
EP4194443A1 (en) Efgr inhibitor, preparation method therefor, and application thereof
JP2020506171A (ja) Ｊａｋ１選択的阻害剤
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
HUE031955T2 (en) New pyrrole pyrimidine compounds as inhibitors of protein kinases
CN107382966B (zh) 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
EP4263501A1 (en) Kinase inhibitors and uses thereof
KR102668390B1 (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
HK40103623A (zh) 激酶抑制剂及其用途
RU2792626C1 (ru) Новый ингибитор киназы pan-raf и его применение
HK40052813A (en) Pyridine salts and process
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
BR112020005455B1 (pt) Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula
HK40005148B (en) Pyridine compound
HK40005148A (en) Pyridine compound

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MOSAICA MEDICINES, INC.

Free format text: FORMER APPLICANT(S): ABM THERAPEUTICS CORPORATION